Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$13.0M
Filings
191
Firms Hired
4
Active Period
2012–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; H.R. 946/S. 1862, ORPHAN Cures Act; S. 3019, No Big Blockbuster Bailouts Act (NOBBBA)
Client expense: — · Firm income: $50,000
Matched citations: H.R. 946
Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; H.R. 946/S. 1862, ORPHAN Cures Act; S. 3019, No Big Blockbuster Bailouts Act (NOBBBA)
Client expense: — · Firm income: $50,000
Matched citations: S. 1862
Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; H.R. 946/S. 1862, ORPHAN Cures Act; S. 3019, No Big Blockbuster Bailouts Act (NOBBBA)
Client expense: — · Firm income: $50,000
Matched citations: S. 3019
FDA regulation of CBD FDA Rare Disease PPRV program/reauthorization Issues related to the regulation of cannabis and CBD, research and development of cannabis-derived therapies Most Favored Nation drug pricing Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act HR 946: Orphan Cures Act Legislation Related to the Repeal or Reform of Orphan Cures Section 232 Tariffs
Client expense: $550,000 · Firm income: —
Matched citations: HR 946
FDA regulation of CBD FDA Rare Disease PPRV program/reauthorization Issues related to the regulation of cannabis and CBD, research and development of cannabis-derived therapies Most Favored Nation drug pricing Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act HR 946: Orphan Cures Act Legislation Related to the Repeal or Reform of Orphan Cures Section 232 Tariffs
Client expense: $490,000 · Firm income: —
Matched citations: HR 946
Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to implementation of the Inflation Reduction Act of 2022; Issues related to Senate Finance Dear Colleague process; H.R. 946/S. 1862, ORPHAN Cures Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 946
Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to implementation of the Inflation Reduction Act of 2022; Issues related to Senate Finance Dear Colleague process; H.R. 946/S. 1862, ORPHAN Cures Act
Client expense: — · Firm income: $50,000
Matched citations: S. 1862
FDA regulation of CBD FDA Rare Disease PPRV program/reauthorization Issues related to the regulation of cannabis and CBD, research and development of cannabis-derived therapies Most Favored Nation drug pricing Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act HR 946: Orphan Cures Act
Client expense: $470,000 · Firm income: —
Matched citations: HR 946
FDA regulation of CBD FDA Rare Disease PPRV program/reauthorization Issues related to the regulation of cannabis and CBD, research and development of cannabis-derived therapies Most Favored Nation drug pricing Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act HR 946: Orphan Cures Act
Client expense: $490,000 · Firm income: —
Matched citations: HR 946
FDA regulation of CBD FDA Rare Disease PPRV program/reauthorization Issues related to the regulation of cannabis and CBD, research and development of cannabis-derived therapies Issues related to the regulation of intoxicating hemp Most Favored Nation drug pricing Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act HR 946: Orphan Cures Act
Client expense: $410,000 · Firm income: —
Matched citations: HR 946
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
2025 · second_quarter · Firm: AVENUE SOLUTIONS
Drug safety, prescription drug abuse, value of prescription drugs; H.R. 946/S. 1862, Orphan Cures Act; Health care issues in H.R.1, To provide for reconciliation pursuant to title II of H. Con. Res. 14 (Public Law No: 119-21); Issues related to drug pricing
Client expense: — · Firm income: $50,000
Matched citations: H. Con. Res. 14
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · second_quarter · Firm: AVENUE SOLUTIONS
Drug safety, prescription drug abuse, value of prescription drugs; H.R. 946/S. 1862, Orphan Cures Act; Health care issues in H.R.1, To provide for reconciliation pursuant to title II of H. Con. Res. 14 (Public Law No: 119-21); Issues related to drug pricing
Client expense: — · Firm income: $50,000
Matched citations: H.R.1
Drug safety, prescription drug abuse, value of prescription drugs; H.R. 946/S. 1862, Orphan Cures Act; Health care issues in H.R.1, To provide for reconciliation pursuant to title II of H. Con. Res. 14 (Public Law No: 119-21); Issues related to drug pricing
Client expense: — · Firm income: $50,000
Matched citations: H.R. 946
Drug safety, prescription drug abuse, value of prescription drugs; H.R. 946/S. 1862, Orphan Cures Act; Health care issues in H.R.1, To provide for reconciliation pursuant to title II of H. Con. Res. 14 (Public Law No: 119-21); Issues related to drug pricing
Client expense: — · Firm income: $50,000
Matched citations: S. 1862
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · second_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
Drug safety, prescription drug abuse, value of prescription drugs; HR 946/S 1862 Orphan Cures Act; Health care issues H.R. 1 (Public Law No: 119-21)
Client expense: — · Firm income: $80,000
Matched citations: H.R. 1
Drug safety, prescription drug abuse, value of prescription drugs; HR 946/S 1862 Orphan Cures Act; Health care issues H.R. 1 (Public Law No: 119-21)
Client expense: — · Firm income: $80,000
Matched citations: HR 946
Drug safety, prescription drug abuse, value of prescription drugs; HR 946/S 1862 Orphan Cures Act; Health care issues H.R. 1 (Public Law No: 119-21)
Client expense: — · Firm income: $80,000
Matched citations: S 1862
FDA regulation of CBD Issues related to the regulation of cannabis and CBD, research and development of cannabis-derived therapies Farm, Food, and National Security Act Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act Drug safety, prescription drug abuse, value of prescription drugs Changes to the Inflation Reduction Act HR 946: Orphan Cures Act
Client expense: $370,000 · Firm income: —
Matched citations: HR 946
Full-Year Continuing Appropriations and Extensions Act, 2025
2025 · first_quarter · Firm: AVENUE SOLUTIONS
Drug safety, prescription drug abuse, value of prescription drugs; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; S. 891, Bipartisan Health Care Act; H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (PL 119-4)
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1968
Drug safety, prescription drug abuse, value of prescription drugs; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; S. 891, Bipartisan Health Care Act; H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (PL 119-4)
Client expense: — · Firm income: $50,000
Matched citations: S. 891
Full-Year Continuing Appropriations and Extensions Act, 2025
2025 · first_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
Drug safety, prescription drug abuse, value of prescription drugs; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; S 891 Bipartisan Healthcare Act; HR 1968 Full Year Continuing Appropriations and Extensions Act of 2025, PL 119-4.
Client expense: — · Firm income: $80,000
Matched citations: HR 1968
Bipartisan Health Care Act
2025 · first_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
Drug safety, prescription drug abuse, value of prescription drugs; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; S 891 Bipartisan Healthcare Act; HR 1968 Full Year Continuing Appropriations and Extensions Act of 2025, PL 119-4.
Client expense: — · Firm income: $80,000
Matched citations: S 891
FDA regulation of CBD Issues related to the regulation of cannabis and CBD, research and development of cannabis-derived therapies Farm, Food, and National Security Act Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act Drug safety, prescription drug abuse, value of prescription drugs Changes to the Inflation Reduction Act HR 946: Orphan Cures Act
Client expense: $380,000 · Firm income: —
Matched citations: HR 946
Drug safety, prescription drug abuse, value of prescription drugs; H.R. 10545, American Relief Act, 2025
Client expense: — · Firm income: $50,000
Matched citations: H.R. 10545
S. 2860 - SAFER Banking Act HR 5539/ S. 3131 - Orphan Cures Act HR 8467 - Farm, Food, and National Security Act of 2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for Fiscal Year 2025 Control status of Epidiolex Changes to Inflation Reduction Act Drug safety, prescription drug abuse, value of prescription drugs Issues related to the regulation of cannabis and CBD Research and development of cannabis-derived therapies
Client expense: $540,000 · Firm income: —
Matched citations: HR 5539
Source: Senate LDA